Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 16.54M | 246.95M | 206.27M | 188.55M | 137.60M | 119.66M |
Gross Profit | 69.39M | 21.87M | 16.56M | 11.84M | 12.37M | 11.14M |
EBITDA | 3.91M | 6.76M | 2.95M | 1.18M | 3.33M | 3.12M |
Net Income | 1.39M | 2.97M | 93.09K | -1.23M | 1.07M | 442.79K |
Balance Sheet | ||||||
Total Assets | 79.61M | 72.42M | 61.61M | 64.56M | 68.68M | 45.64M |
Cash, Cash Equivalents and Short-Term Investments | 1.77M | 3.83M | 2.75M | 2.05M | 18.32M | 2.81M |
Total Debt | 5.18M | 5.89M | 6.87M | 12.41M | 17.21M | 14.20M |
Total Liabilities | 44.53M | 40.24M | 32.10M | 34.69M | 37.18M | 33.28M |
Stockholders Equity | 34.91M | 31.79M | 29.54M | 29.86M | 31.50M | 12.36M |
Cash Flow | ||||||
Free Cash Flow | 4.64M | 2.83M | 3.57M | -12.08M | -6.15M | -6.78M |
Operating Cash Flow | 8.67M | 6.41M | 8.91M | -7.85M | -2.56M | 2.77M |
Investing Cash Flow | -2.58M | -2.81M | -2.30M | -3.16M | -3.06M | -8.45M |
Financing Cash Flow | -2.07M | -2.53M | 1.11M | -2.57M | 15.65M | 4.36M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | €63.25M | 14.57 | 13.04% | 1.09% | 16.88% | -15.24% | |
52 Neutral | €50.29M | -31.42 | 1.44% | ― | -11.23% | 43.27% | |
51 Neutral | €11.44M | -3.97 | -46.63% | ― | -2.10% | 64.37% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
Omer-Decugis & Cie has been authorized by its General Meeting to implement a share buyback program, allowing the company to purchase up to 10% of its share capital. The program aims to support various corporate objectives, including stock option plans, employee shareholding, and potential external growth operations, with a maximum purchase price set at 25 euros per share.